John P. Sfakianos, MD

Articles by John P. Sfakianos, MD

John Sfakianos, MD, on integrating ctDNA into bladder cancer trials

ByJohn P. Sfakianos, MD

October 1st 2026

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

ByJohn P. Sfakianos, MD

September 9th 2026

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC

ByJohn P. Sfakianos, MD

January 29th 2026

John P. Sfakianos, MD, shares the clinical rationale for the phase 2 ENHANCE trial, evaluating the addition of NKG2A inhibition to PD-1/PD-L1 inhibition in NMIBC.

John Sfakianos, MD, on moving immunotherapy earlier in NMIBC treatment pathway

ByJohn P. Sfakianos, MD

January 21st 2026

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

John P. Sfakianos, MD, on the role of urine-based biomarkers in microhematuria evaluation

ByJohn P. Sfakianos, MD

September 16th 2025

John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.